Search Results - "Milassin, A"

Impact de la pandémie Covid 19 sur les adolescents asthmatiques en Alsace, durant le premier confinement by Gault-Milassin, A., Eyer, D., De Blay, F., Metz-Favre, C.

Get full text

P532 Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agents by Rutka, M, Szántó, K, Bor, R, Bálint, A, Fábián, A, Milassin, A, Szepes, Z, Farkas, K, Molnar, T

“…Abstract Background Vedolizumab it is a promising agent in IBD patients refractory to anti-TNF therapy. However, a potential slower response has been…”
Get full text

P580 Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study by Balint, A., Torocsik, D., Palatka, K., Szepes, Z., Szucs, M., Ferenci, T., Nagy, F., Farkas, K., Fábián, A., Bor, R., Milassin, A., Rutka, M., Molnar, T.

Get full text

P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data by Molnár, T., Farkas, K., Rutka, M., Ferenci, T., Nagy, F., Bálint, A., Bor, R., Milassin, A., Fábián, A., Végh, Z., Kürti, Z., Lakatos, P.L., Szepes, Z.

Get full text

P317 Postoperative complications, outcome, quality of life and self-image after ileal pouch-anal anastomosis in patients operated due to acute, severe or chronic, therapy refractory ulcerative colitis by Balint, A., Czinderi, V., Szucs, M., Rutka, M., Farkas, K., Szepes, Z., Nagy, F., Fábián, A., Bor, R., Milassin, A., Lázár, G., Molnár, T.

Get full text

P654 Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre study by Farkas, K, Elekes, G, Kata, D, Földesi, I, Lada, S, Ferenci, T, Madácsy, T, Rutka, M, Bálint, A, Bor, R, Fábián, A, Milassin, A, Szepes, Z, Nagy, F, Maléth, J, Molnár, T

“…Abstract Background The introduction of anti-TNF therapy has dramatically changed the treatment of refractory inflammatory bowel disease (IBD-Crohn’s disease…”
Get full text

P534 IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry by Milassin, A, Rutka, M, Farkas, K, Bálint, A, Bor, R, Fábián, A, Szepes, Z, Szamosi, T, Szántó, K, Miheller, P, Barta, Z, Banai, J, Kovács, Á, Salamon, Á, Lakatos, L, Lakner, L, Palatka, K, Papp, M, Schafer, E, Novák, J, Erdélyi, Z, Kürti, Z, Lakatos, P L, Sarlós, P, Szigeti, N, Veres, G, Zaránd, A, Gelley, A, Vincze, Á, Nagy, F, Molnár, T

“…Abstract Background Inflammatory bowel diseases (IBD – Crohn’s disease (CD); ulcerative colitis (UC)) are associated with an increased risk of colorectal…”
Get full text

P739 Characteristic of IBD related colorectal cancers observed in different Hungarian centers by Rutka, M., Farkas, K., Tiszlavicz, L., Szepes, Z., Balint, A., Bor, R., Fábián, A., Milassin, A., Miheller, P., Banai, J., Salamon, A., Novák, J., Vincze, A., Lakatos, L., Palatka, K., Szamosi, T., Kovács, A., Gelley, A., Nagy, F., Molnar, T.

Get full text

P279 Children born to mothers with inflammatory bowel disease – Is there any risk for newborns' complication and development during the childhood? by Farkas, K., Szántό, K., Vass, N., Szűcs, D., Demcsák, A., Lada, S., Nyári, T., Milassin, A., Rutka, M., Bor, R., Bálint, A., Fábián, A., Nagy, F., Szepes, Z., Marik, A., Molnár, T.

Get full text

P840 IBD-related malignancies and mortalities observed in 2015–2017: 3 years’ results from the prospective nationwide Hungarian registry by Molnar, T, Nagy, F, Fritz, P, Lakatos, L, Erdélyi, Z, Miheller, P, Szamosi, T, Schafer, E, Vincze, A, Sarlós, P, Banai, J, Kovács, A, Novák, J, Salamon, A, Szepes, A, Szigeti, N, Juhász, M, Müllner, K, Barta, Z, Kadenczki, O, Gelley, A, Palatka, K, Papp, M, Zaránd, A, Lakatos, P, Veres, G, Rutka, M, Balint, A, Bor, R, Milassin, A, Fábián, A, Szepes, Z, Farkas, K

“…Abstract Background Inflammatory bowel diseases (IBD-Crohn’s disease (CD); ulcerative colitis (UC)) are lifelong inflammatory conditions of the…”
Get full text

Impact de la pandémie Covid 19 sur les adolescents asthmatiques en Alsace, durant le premier confinement by Gault-Milassin, A., Eyer, D., De Blay, F., Metz-Favre, C.

“…L’Alsace a été particulièrement impactée par la première vague épidémique liée au Covid 19. Nous avons évalué l’impact de cette crise sanitaire sur des…”
Get full text

P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it’s time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study by Molnár, T, Resál, T, Bacsur, P, Rutka, M, Szántó, K, Bálint, A, Milassin, Á, Fábián, A, Bor, R, Szepes, Z, Farkas, K

“…Abstract Background Iron deficiency (ID) is often a neglected condition in inflammatory bowel disease (IBD), even though it is one of the most common…”
Get full text

P610 Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary by Molnár, T, Nagy, F, Szepes, Z, Farkas, K, Bor, R, Bálint, A, Milassin, Á, Fábián, A, Rutka, M, Szántó, K

“…Abstract Background Anti-TNF therapy showed high efficacy in the maintenance of remission in ulcerative colitis (UC) based on study results. However, there is…”
Get full text

P748 Characteristics of inflammatory bowel diseases in different stage of adolescence by Szántó, K J, Bálint, A, Bor, R, Fábián, A, Milassin, Á, Rutka, M, Szepes, Z, Vass, N, Molnár, T, Farkas, K

“…Abstract Background There is a lack of data regarding clinical and therapeutic characteristics in middle and late adolescent inflammatory bowel diseases (IBD)…”
Get full text

P371 Outcome of immediate infliximab optimisation based on rapid assessment of serum drug and faecal calprotectin concentrations in Crohn’s disease by Farkas, K, Szántó, K, Kata, D, Bálint, A, Milassin, Á, Fábián, A, Bor, R, Rutka, M, Szepes, Z, Soós, I, Nagy, F, Földesi, I, Molnár, T

“…Abstract Background Dose intensification strategy based on the parallel assessment of clinical symptoms, serum and faecal biomarkers and serum infliximab (IFX)…”
Get full text

P817 Influence of inflammatory bowel diseases on depression and suicidal risk: a questionnaire-based survey by Molnár, T, Miheller, P, Sarlós, P, Sánta, A, Juhász, A, Hamvas, E, Nyári, T, Szántó, K J, Bor, R, Fábián, A, Bálint, A, Milassin, Á, Rutka, M, Szepes, Z, Farkas, K

“…Abstract Background Inflammatory bowel diseases (IBD) patients are at increased risk for mental health problems. Managing IBD patients requires cooperation…”
Get full text

P357 Importance of stool drug monitoring in anti-TNF-treated patients by Bacsur, P, Szántó, K, Madácsy, T, Kata, D, Ferenci, T, Rutka, M, Bálint, A, Bor, R, Fábián, A, Milassin, Á, Elekes, G, Szepes, Z, Nagy, F, Földesi, I, Maléth, J, Farkas, K, Molnár, T

“…Abstract Background Anti-tumour necrosis factor (TNF) therapy has dramatically changed the treatment of inflammatory bowel disease (IBD). The relationship…”
Get full text

P628 Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiences by Szántó, K, Farkas, K, Rutka, M, Bálint, A, Bor, R, Milassin, Á, Fábián, A, Szepes, Z, Nagy, F, Vass, N, Szűcs, D, Molnár, T

“…Abstract Background inflammatory bowel disease s (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) are usually diagnosed in adolescence or young adulthood…”
Get full text

P674 Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre by Szántó, K, Szíjártó, A L, Kata, D, Földesi, I, Mezei, Z A, Fábián, A, Bálint, A, Bor, R, Farkas, K, Milassin, Á, Rutka, M, Szepes, Z, Nagy, F, Bubán, T, Lovas, S, Palatka, K, Molnár, T

“…Abstract Background Clinical data suggest a synergistic effect between thiopurine and anti-tumour necrosis factor (anti-TNF) therapy in IBD. However,…”
Get full text

P495 Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases? by Fábián, A, Szántó, K, Szíjártó, A L, Bor, R, Bálint, A, Farkas, K, Milassin, Á, Rutka, M, Szepes, Z, Földesi, I, Kata, D, Mezei, Z A, Lovas, S, Palatka, K, Molnár, T

“…Abstract Background Clinical data suggest a synergistic effect between thiopurine and anti-tumour necrosis factor (anti-TNF) therapy both in ulcerative colitis…”
Get full text